Introduction: Atrial fibrillation is the most common complication after coronary artery bypass surgery. It’s known that increases morbidity and mortality after Coronary artery bypass graft (CABG) surgery and also leads to increased length of stay in the ICU and the hospital. The purpose of this study is to evaluate the prophylactic effect of amiodarone in reducing the incidence of atrial fibrillation after coronary artery bypass surgery. Materials and Methods: In this randomized clinical trial study, 124 elective patients scheduled for CABG surgery were enrolled based on inclusion and exclusion criteria and randomly divided into two equal groups. Patients of intervention group before anesthesia, intravenously received 300 mg amiodarone medication and the control group received normal saline. Up to 24 hours after coronary artery bypass surgery, the incidence of atrial fibrillation in the two groups was observed. Results: The incidence of atrial fibrillation after CABG in intervention group was 16 people and in the control group was 35 people. The prevalence of atrial fibrillation compared between two groups using chi-square analysis showed that there is a significant difference between two groups (p=0.037) and the incidence of atrial fibrillation in control group was significantly lower than the intervention group. Conclusion: Although in the study the amiodarone medication was used with lower dose and duration compared with other studies, but the results of this study showed that even with the same protocol it is possible to use amiodarone for prevention of atrial fibrillation after coronary artery bypass surgery.
Key words: Amiodarone, Arrhythmia, Atrial Fibrillation, Coronary Artery Bypass, Prevention Clinical Trial.